SCHEMBL6301057

SCHEMBL6301057

Cc1nc2ccc(C(=O)NS(=O)(=O)c3ccc(Cl)s3)nc2n1Cc1ccc(COc2ccccc2)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.39
THRB P10828 1/20 0.39
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PPARG P37231 4/20 0.37
BCL2L1 Q07817 6/20 0.35
MCL1 Q07820 6/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ABCB1 P08183 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
P2RY12 Q9H244 2/20 0.34
KMT2A Q03164 2/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6299297 0.93 MAPT (0.36) TP53MAPTALDH1A1SMN1; SMN2PPARG
SCHEMBL6134259 0.93 S1PR1 (0.40) TP53THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL6306004 0.90 PPARG (0.41) TP53THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL6135222 0.90 BCL2L1 (0.43) MAPTALDH1A1SMN1; SMN2PPARGBCL2L1
SCHEMBL6299728 0.87 BCL2L1 (0.43) MAPTALDH1A1SMN1; SMN2BCL2L1MCL1
SCHEMBL6299271 0.86 MAPT (0.41) TP53THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL6305630 0.86 S1PR1 (0.39) TP53MAPTALDH1A1SMN1; SMN2PPARG
SCHEMBL6300042 0.85 PPARG (0.47) MAPTALDH1A1SMN1; SMN2PPARGHTT
SCHEMBL6299424 0.84 ALDH1A1 (0.40) TP53THRBMAPTALDH1A1SMN1; SMN2
SCHEMBL6299422 0.84 ALDH1A1 (0.40) TP53THRBMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 TP53 4884/4885THRB 1313/4885MAPT 4591/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM TP53 4849/4885THRB 1284/4885MAPT 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.